Onderneming Ayala Pharmaceuticals, Inc.
Aandelen
ADXS
US0076244062
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,665 USD | +19,82% | +16,26% | -0,30% |
Vakgebied
Aantal werknemers: 21
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ken Berlin
CEO | Chief Executive Officer | 59 | 01-04-18 |
Roy Golan
DFI | Director of Finance/CFO | 50 | 19-10-23 |
Shmuel Tuvia
CTO | Chief Tech/Sci/R&D Officer | - | 01-05-22 |
General Counsel | - | 01-01-18 | |
Human Resources Officer | - | 01-01-19 | |
Dana Gelbaum
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Sidransky
CHM | Chairman | 64 | 01-11-17 |
Roni Appel
BRD | Director/Board Member | 57 | 01-11-04 |
Murray Goldberg
BRD | Director/Board Member | 79 | 01-12-17 |
Robert Spiegel
BRD | Director/Board Member | 73 | 01-12-17 |
Pini Orbach
BRD | Director/Board Member | - | 19-10-23 |
Ken Berlin
CEO | Chief Executive Officer | 59 | 01-04-18 |
Director/Board Member | 53 | 01-08-20 | |
Bridget Martell
BRD | Director/Board Member | 58 | 19-10-23 |
Yuval Cabilly
BRD | Director/Board Member | 44 | 19-10-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 42 672 852 | 42 632 547 ( 99,91 %) | 39 452 ( 0,0925 %) | 99,91 % |
Bedrijfsgegevens
Ayala Pharmaceuticals, Inc.
9 Deer Park Drive Suite K-1
08852, Monmouth Junction
+
http://www.ayalapharma.comSector
Chiffre d''affaires - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,30% | 28,35 mln. | |
+0,36% | 42,86 mld. | |
+11,66% | 42,74 mld. | |
+44,30% | 41,36 mld. | |
-6,20% | 27,68 mld. | |
+5,39% | 25,15 mld. | |
-24,40% | 18,63 mld. | |
+27,50% | 12,37 mld. | |
-3,19% | 11,92 mld. | |
+7,00% | 11,21 mld. |
- Beurs
- Aandelen
- Koers ADXS
- Onderneming Ayala Pharmaceuticals, Inc.